Digital health company Adherium (ASX:ADR) has appointed Francis White as the vice president of global business development based in the UK.
CEO Rick Legleiter said, “Since Adherium’s founding, pharmaceutical clinical trials have been the core business. We have learned and benefited significantly from these partner relationships to establish an exciting inflection point for the Company with a new digital services portfolio to generate meaningful revenue from remote patient monitoring.
"The UK is home to global leaders in respiratory medications and therapeutics and Francis joining our leadership team is a key staffing milestone for a new strategic sales approach to acquiring new customers while supporting current customers to grow revenue in this market segment.
"With so much non-COVID-19 clinical trial work stopped or put on hold due to pandemic workload, lack of hospital access, and difficulty recruiting participants, we expect a continued resurgence to pre-pandemic levels globally.
"Given the Company’s historical experience, now is the time to leverage our digital platform including our new, next-generation digital inhalers with physiological parameters offering an unmatched value proposition to clinical partners that has never been stronger.
"Appointing Francis to lead this newly created worldwide commercial role from his UK base and given his key account management (KAM), sales and marketing experience is a statement of our commitment to international pharmaceutical companies, contract research organizations (CROs) and their related parties.”
Mr White most recently served as the managing director of Olympus Medical UKIE. He previously served as vice president of sales and business development at AliveCor.
“I couldn’t be more excited to bring our brand new, revolutionary, data-rich, digital Inhaler platform to new and existing pharmaceutical and CRO customers across the world," he said. "This industry-leading physiological sensing technology brings the potential to surface unprecedented, and previously unattainable, insights and novel outcome measures. A new strategy engaging at customer senior management levels will expand our partnerships and reach enabling us to power many more effective clinical trials and at the same time, help meet carbon reduction targets.”